Showing results (51-60 of 103) with videos related to

Sort By:
Pageof 11
Seminars in Oncology|April 1, 1995
Preclinical evaluation of docetaxel (Taxotere)F Lavelle, M C Bissery, C Combeau, et al.
Cell Adhesion and Communication|May 1, 1993
Amphibian Pleurodeles waltl fibronectin: cDNA cloning and developmental expression of spliced variantsL Clavilier, J F Riou, D L Shi, et al.
Biochemistry|August 2, 1994
Molecular interactions of DNA-topoisomerase I and II inhibitor with DNA and topoisomerases and in ternary complexes: binding modes and biological effects for intoplicine derivativesI Nabiev, I Chourpa, J F Riou, et al.
NCI Monographs : a Publication of the National Cancer Institute|January 1, 1987
In vivo and in vitro stimulation by antitumor drugs of the topoisomerase II-induced cleavage sites in c-myc proto-oncogeneJ F Riou, M J Vilarem, C J Larsen, et al.
Biochemistry|April 1, 1997
DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycinC Bailly, J F Riou, P Colson, et al.
Oncogene|April 21, 2001
Human ARF protein interacts with topoisomerase I and stimulates its activityL Karayan, J F Riou, P Séité, et al.
Biochemical Pharmacology|July 1, 1986
The in vitro involvement of topoisomerase II in the activity of aza-ellipticine analogues is not correlated with drug activity on isolated nucleiM J Vilarem, J F Riou, E Multon, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 10, 1998
Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38H M Dodds, M C Haaz, J F Riou, et al.
Physical Review Letters|December 13, 2006
Guided quasicontinuous atom laserW Guerin, J-F Riou, J P Gaebler, et al.
Anti-Cancer Drug Design|January 8, 2000
The development of telomerase inhibitors: the G-quartet approachJ L Mergny, P Mailliet, F Lavelle, et al.
Pageof 11